[go: up one dir, main page]

DK590288D0 - Kemiske forbindelser - Google Patents

Kemiske forbindelser

Info

Publication number
DK590288D0
DK590288D0 DK590288A DK590288A DK590288D0 DK 590288 D0 DK590288 D0 DK 590288D0 DK 590288 A DK590288 A DK 590288A DK 590288 A DK590288 A DK 590288A DK 590288 D0 DK590288 D0 DK 590288D0
Authority
DK
Denmark
Prior art keywords
pellet
supernatant
fraction
components
new
Prior art date
Application number
DK590288A
Other languages
English (en)
Inventor
Alan G Barbour
Sven Bergstroem
Louis Magnarelli
Original Assignee
Symbicom Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8146053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK590288(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of DK590288D0 publication Critical patent/DK590288D0/da
Priority to DK590288A priority Critical patent/DK590288D0/da
Application filed by Symbicom Ab filed Critical Symbicom Ab
Priority to DE68929550T priority patent/DE68929550T2/de
Priority to DE68927891T priority patent/DE68927891T2/de
Priority to AU44953/89A priority patent/AU639667B2/en
Priority to EP93201345A priority patent/EP0565208B1/en
Priority to DE68929369T priority patent/DE68929369T2/de
Priority to PCT/DK1989/000248 priority patent/WO1990004411A1/en
Priority to AT93201345T priority patent/ATE212376T1/de
Priority to EP95203128A priority patent/EP0711563B1/en
Priority to AT89912228T priority patent/ATE150318T1/de
Priority to AT00125910T priority patent/ATE432988T1/de
Priority to EP00125910A priority patent/EP1092774B1/en
Priority to DE68929565T priority patent/DE68929565D1/de
Priority to CA002001328A priority patent/CA2001328C/en
Priority to EP89912228A priority patent/EP0445135B1/en
Priority to DK199100750A priority patent/DK175844B1/da
Priority to FI911964A priority patent/FI112366B/fi
Priority to NO91911602A priority patent/NO911602L/no
Priority to US08/137,175 priority patent/US5777095A/en
Priority to US08/079,601 priority patent/US5523089A/en
Priority to US08/262,220 priority patent/US6054296A/en
Priority to US08/264,036 priority patent/US6300101B1/en
Priority to US08/320,416 priority patent/US5582990A/en
Priority to US08/375,993 priority patent/US5688512A/en
Priority to US08/470,627 priority patent/US6203798B1/en
Priority to US08/470,638 priority patent/US6509017B1/en
Priority to US08/466,393 priority patent/US6183986B1/en
Priority to US08/479,017 priority patent/US6143872A/en
Priority to US08/471,019 priority patent/US6083722A/en
Priority to US08/588,637 priority patent/US7094391B1/en
Priority to JP9526117A priority patent/JP2000507209A/ja
Priority to FI981624A priority patent/FI981624L/fi
Priority to AU17470/97A priority patent/AU740048B2/en
Priority to IL12532397A priority patent/IL125323A0/xx
Priority to EP97904758A priority patent/EP0876156A4/en
Priority to PCT/US1997/000557 priority patent/WO1997026006A1/en
Priority to ZA9700459A priority patent/ZA97459B/xx
Priority to NO983220A priority patent/NO983220L/no
Priority to US09/973,406 priority patent/US6814970B2/en
Priority to DK200401413A priority patent/DK200401413A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK590288A 1919-10-24 1988-10-24 Kemiske forbindelser DK590288D0 (da)

Priority Applications (40)

Application Number Priority Date Filing Date Title
DK590288A DK590288D0 (da) 1988-10-24 1988-10-24 Kemiske forbindelser
CA002001328A CA2001328C (en) 1988-10-24 1989-10-24 Borrelia antigen
EP89912228A EP0445135B1 (en) 1988-10-24 1989-10-24 Immogenically active fractions of borrelia burgdorferi
AT93201345T ATE212376T1 (de) 1988-10-24 1989-10-24 Dns fragmente, die für borrelia burgdorferi ospa kodieren, verfahren zur herstellung von ospa polypeptiden, und diagnostische verfahren basierend auf diesen dns fragmenten
AT00125910T ATE432988T1 (de) 1988-10-24 1989-10-24 Borrelia burgdorferi ospa polypeptid zur immunisierung gegen lymeborreliose
AU44953/89A AU639667B2 (en) 1988-10-24 1989-10-24 Immunogenically active fractions of borrelia burgdorferi
EP93201345A EP0565208B1 (en) 1988-10-24 1989-10-24 DNA fragments encoding OspA of Borrelia burgdorferi, method of preparation of OspA polypeptides and diagnostic methods based upon said DNA fragments
DE68929369T DE68929369T2 (de) 1988-10-24 1989-10-24 DNS Fragmente, die für Borrelia burgdorferi OspA kodieren, Verfahren zur Herstellung von OspA Polypeptiden, und diagnostische Verfahren basierend auf diesen DNS Fragmenten
PCT/DK1989/000248 WO1990004411A1 (en) 1988-10-24 1989-10-24 Immunogenically active fractions of borrelia burgdorferi
DE68929550T DE68929550T2 (de) 1988-10-24 1989-10-24 Im Wesentlichen reines ganzes OspaA-Protein, frei von anderen B. burgdorferi-Materialien
EP95203128A EP0711563B1 (en) 1988-10-24 1989-10-24 Substantially pure entire ospa protein free from other b. burgdorferi related material
AT89912228T ATE150318T1 (de) 1988-10-24 1989-10-24 Fraktionen von borella burgdorferi mit immunogener wirkung
DE68927891T DE68927891T2 (de) 1988-10-24 1989-10-24 Fraktionen von BORELLA BURGDORFERI mit immunogener Wirkung
EP00125910A EP1092774B1 (en) 1988-10-24 1989-10-24 Borrelia burgdorferi OspA polypeptide for immunization against Lyme disease
DE68929565T DE68929565D1 (de) 1988-10-24 1989-10-24 Borrelia burgdorferi OspA Polypeptid zur Immunisierung gegen Lymeborreliose
NO91911602A NO911602L (no) 1988-10-24 1991-04-23 Immunogent aktive fraksjoner av borrelia burgdorferi.
FI911964A FI112366B (fi) 1988-10-24 1991-04-23 Menetelmä organismin Borrelia burgdorferi OspA -polypeptidin ja sitä tuottavan organismin valmistamiseksi ja menetelmässä käytettäviä välineitä
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
US08/137,175 US5777095A (en) 1988-10-24 1992-10-22 Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US08/079,601 US5523089A (en) 1988-10-24 1993-06-22 Borrelia antigen
US08/262,220 US6054296A (en) 1988-10-24 1994-06-20 66 kDa antigen from Borrelia
US08/264,036 US6300101B1 (en) 1988-10-24 1994-06-22 Methods and compositions including a 13kD B. burgdorferi protein
US08/320,416 US5582990A (en) 1988-10-24 1994-10-03 DNA encoding borrelia burgdorferi OspA and a method for diagnosing borrelia burgdorferi infection
US08/375,993 US5688512A (en) 1988-10-22 1995-01-20 Borrelia antigen
US08/470,627 US6203798B1 (en) 1988-10-24 1995-06-06 Borrelia antigen
US08/470,638 US6509017B1 (en) 1919-10-24 1995-06-06 66 KDA antigen from Borrelia
US08/466,393 US6183986B1 (en) 1988-10-24 1995-06-06 OspA DNA and lyme disease vaccine
US08/479,017 US6143872A (en) 1988-10-24 1995-06-06 Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US08/471,019 US6083722A (en) 1988-10-24 1995-06-06 Borrelia antigen
US08/588,637 US7094391B1 (en) 1988-10-24 1996-01-19 Compositions and methods for administering Borrelia burgdorferi antigens
PCT/US1997/000557 WO1997026006A1 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
EP97904758A EP0876156A4 (en) 1988-10-24 1997-01-17 COMPOSITIONS AND METHODS FOR THE APPLICATION OF ANTIGENS FOR BORRELIA BURGDORFERI
JP9526117A JP2000507209A (ja) 1988-10-24 1997-01-17 ボレリア・ブルグドフェリ（Ｂｏｒｒｅｌｉａ ｂｕｒｇｄｏｒｆｅｒｉ）抗原を投与するための組成物および方法
FI981624A FI981624L (fi) 1988-10-24 1997-01-17 Koostumukset ja menetelmät Borrelia burgdorferi antigeenien annostelemiseksi
AU17470/97A AU740048B2 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
IL12532397A IL125323A0 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
ZA9700459A ZA97459B (en) 1988-10-24 1997-01-20 Composition and methods for administering borrelia burgdorferi antigens.
NO983220A NO983220L (no) 1988-10-24 1998-07-13 Sammensetninger og fremgangsmåter for å administrere Borrelia Burgdorferi-antigener
US09/973,406 US6814970B2 (en) 1988-10-24 2001-10-09 Methods and compositions including a 13 kD B. burgdorferi protein
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK590288A DK590288D0 (da) 1988-10-24 1988-10-24 Kemiske forbindelser

Publications (1)

Publication Number Publication Date
DK590288D0 true DK590288D0 (da) 1988-10-24

Family

ID=8146053

Family Applications (3)

Application Number Title Priority Date Filing Date
DK590288A DK590288D0 (da) 1919-10-24 1988-10-24 Kemiske forbindelser
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Country Status (10)

Country Link
US (6) US5523089A (da)
EP (4) EP1092774B1 (da)
AT (3) ATE212376T1 (da)
AU (1) AU639667B2 (da)
CA (1) CA2001328C (da)
DE (4) DE68929565D1 (da)
DK (3) DK590288D0 (da)
FI (1) FI112366B (da)
NO (1) NO911602L (da)
WO (1) WO1990004411A1 (da)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US6054296A (en) 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US6300101B1 (en) * 1988-10-24 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions including a 13kD B. burgdorferi protein
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
ZA907419B (en) * 1989-09-19 1991-07-31 Max Planck Gesellschaft Vaccine against lyme disease
US5470712A (en) * 1990-03-05 1995-11-28 Us Health Antigenic proteins of Borrelia burgdorferi
SG122738A1 (en) 1990-06-15 2006-06-29 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
EP0465204B1 (en) * 1990-07-06 2000-09-20 American Home Products Corporation Vaccine against Lyme disease
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US5436000A (en) * 1991-01-11 1995-07-25 University Of Texas System Flagella-less borrelia
EP0588958A1 (en) * 1991-06-13 1994-03-30 Pacific Biotech Inc. Assay for the detection of specific ligands
US5324630A (en) * 1991-06-28 1994-06-28 The Regents Of The University Of California Methods and compositions for diagnosing lyme disease
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
AU666326B2 (en) * 1991-08-15 1996-02-08 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Osp A proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
WO1993008299A1 (en) * 1991-10-18 1993-04-29 Connaught Laboratories Inc. Preparation of recombinant borrelia proteins
ES2194010T3 (es) * 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5308753A (en) * 1992-02-20 1994-05-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for purifying and detecting IGM antibodies
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
BE1006728A3 (fr) * 1993-02-19 1994-11-29 Wallone Region Sondes d'acides nucleiques specifiques au spirochete borrelia burgdorferi.
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
WO1995027504A1 (en) 1994-04-11 1995-10-19 Solvay Animal Health, Inc. Borrelia burgdorferi bacterin
US6087097A (en) * 1994-05-12 2000-07-11 Mayo Foundation For Medical Education And Research PCR detection of Borrelia burgdorferi
US6214355B1 (en) 1995-04-24 2001-04-10 Texas A & M University System DbpA compositions
US6312907B1 (en) 1995-04-24 2001-11-06 The Texas A & M University System DbpA compositions and methods of use
US6248517B1 (en) 1995-04-24 2001-06-19 The Texas A & M University System Decorin binding protein compositions and methods of use
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU6028396A (en) * 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
US6045804A (en) * 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
JP2000510339A (ja) * 1996-05-08 2000-08-15 イエール ユニバーシティ インビボで発現されるＢ．ｂｕｒｇｄｏｒｆｅｒｉポリペプチド
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
DE69740033D1 (de) 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
DE19632862B4 (de) 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US6902893B1 (en) * 1997-06-20 2005-06-07 Gil H. Choi Lyme disease vaccines
EP1009859A1 (en) * 1997-06-20 2000-06-21 Human Genome Sciences Lyme disease vaccines
ATE337335T1 (de) * 1997-06-30 2006-09-15 Univ Tulane Oberflächenantigene und proteine für zusammensetzungen zu diagnose und vorbeugung der lyme-kkrankheit
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
AU8881198A (en) * 1997-09-10 1999-03-29 Symbicom A.B. P13 antigens from (borrelia)
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
GB9811219D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
WO2000078345A1 (en) * 1999-06-21 2000-12-28 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6689364B2 (en) 2000-03-21 2004-02-10 Tufts University Borrelia burgdorferi polypeptides and uses thereof
WO2001092870A2 (de) * 2000-06-02 2001-12-06 Zeptosens Ag Kit und verfahren zur multianalytbestimmung
DK1311540T3 (da) 2000-08-18 2008-04-28 Brookhaven Sciences Ass Llc Ændret OspA af Borrelia Burgdorferi
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
US20040033623A1 (en) * 2002-08-16 2004-02-19 Igenex, Inc. Assay for detection of antigen in bodily fluid
US20050058661A1 (en) * 2002-10-18 2005-03-17 Sykes Kathryn F. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus Borrelia
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
WO2004089969A2 (en) * 2003-04-02 2004-10-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
US20060051060A1 (en) * 2003-07-03 2006-03-09 Henry Dorovanessian Method and system for digitally recording broadcast content
WO2006026248A1 (en) 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US20060281139A1 (en) * 2005-05-23 2006-12-14 Viramed Biotech Ag Carrier and method for the detection of anti-borrelia antibodies and test kit for use in the diagnosis of Lyme borreliosis infections
US7663212B2 (en) 2006-03-21 2010-02-16 Infineon Technologies Ag Electronic component having exposed surfaces
US7541681B2 (en) * 2006-05-04 2009-06-02 Infineon Technologies Ag Interconnection structure, electronic component and method of manufacturing the same
JP5177824B2 (ja) 2006-11-03 2013-04-10 シェーリング−プラウ・リミテッド イヌのライム病のワクチン
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2009126816A1 (en) * 2008-04-09 2009-10-15 Ventria Bioscience Production of ospa for lyme disease control
AU2009241645B2 (en) 2008-05-02 2014-07-17 Blink Therapeutics Limited Products and methods for stimulating an immune response
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
EP2545071A2 (en) 2010-03-09 2013-01-16 Maksyutov, Amir Polyepitope constructs and methods for their preparation and use
MX375965B (es) 2010-05-14 2025-03-07 Baxalta Inc Genes ospa quimericos, proteinas, y metodos para usar los mismos.
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
KR20130101067A (ko) 2010-09-27 2013-09-12 코넬 유니버시티 라임병의 진단 방법
WO2012047970A1 (en) * 2010-10-05 2012-04-12 Board Of Trustees Of Michigan State University Regulatory factors controlling oil biosynthesis in microalgae and their use
CN104640563A (zh) 2012-07-27 2015-05-20 巴克斯特国际公司 包含嵌合的ospa分子的组合物及其使用方法
WO2016134006A1 (en) * 2015-02-17 2016-08-25 Colorado State University Research Foundation High sensitivity method for early lyme disease detection
CA3020634A1 (en) 2016-04-14 2017-10-19 Merial, Inc. Multi-dose compositions containing an antimicrobial polyamide or octenidine preservative
WO2018227109A1 (en) 2017-06-08 2018-12-13 Colorado State University Research Foundation Differentiation of lyme disease and southern tick-associated rash illness
EP3898666A2 (en) 2018-12-17 2021-10-27 Immudex ApS Panel comprising borrelia mhc multimers
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
JP2025519477A (ja) 2022-06-07 2025-06-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔ細胞活性を調節するための多重特異性分子及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4888276A (en) * 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) * 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit

Also Published As

Publication number Publication date
EP0565208B1 (en) 2002-01-23
US5582990A (en) 1996-12-10
DE68927891D1 (de) 1997-04-24
EP1092774A3 (en) 2001-04-25
CA2001328C (en) 2005-12-13
FI112366B (fi) 2003-11-28
ATE432988T1 (de) 2009-06-15
EP0711563A1 (en) 1996-05-15
EP0445135B1 (en) 1997-03-19
DK200401413A (da) 2004-09-17
NO911602L (no) 1991-06-24
EP0445135A1 (en) 1991-09-11
ATE150318T1 (de) 1997-04-15
DE68929550D1 (de) 2007-03-08
US5688512A (en) 1997-11-18
DE68929369D1 (de) 2002-03-14
WO1990004411A1 (en) 1990-05-03
US6203798B1 (en) 2001-03-20
ATE212376T1 (de) 2002-02-15
CA2001328A1 (en) 1991-04-24
US6083722A (en) 2000-07-04
EP1092774A2 (en) 2001-04-18
DK75091D0 (da) 1991-04-23
AU639667B2 (en) 1993-08-05
EP0711563B1 (en) 2007-01-17
EP0565208A1 (en) 1993-10-13
US5523089A (en) 1996-06-04
DK175844B1 (da) 2005-03-29
NO911602D0 (no) 1991-04-23
FI911964A0 (fi) 1991-04-23
US6183986B1 (en) 2001-02-06
DE68929369T2 (de) 2002-09-26
DE68929550T2 (de) 2007-12-06
DE68929565D1 (de) 2009-07-16
DE68927891T2 (de) 1997-10-02
EP1092774B1 (en) 2009-06-03
DK75091A (da) 1991-06-12
AU4495389A (en) 1990-05-14

Similar Documents

Publication Publication Date Title
DK590288D0 (da) Kemiske forbindelser
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
IE791115L (en) Genetically engineered protein.
WO2000073316A3 (en) Virus immunologic determinants
CA2149319A1 (en) Haemophilus outer membrane protein
HUP9800730A2 (hu) Expressziós rendszer heterológ antigének fúziós proteinként történő expresszáltatására
IL65565A (en) Plasmids coding for b.thuringiensis crystal protein,their production and their use in creating genetically engineered bacterial strains
ATE387458T1 (de) Fas-antigenbindender ligand
EP0185076A4 (da)
FR2669338B1 (da)
CA2093427A1 (en) Molecular clones of hiv-1 and uses thereof
Clezardin et al. Isolation of thrombospondin released from thrombinstimulated human platelets by fast protein liquid chromatography on an anion-exchange mono-q column
FI970428A0 (fi) Soluja, joissa on CD4-houkutusreseptoreita ja vastaavia molekyylejä ja menetelmiä
ATE122055T1 (de) Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung.
Reeves et al. Partial purification and characterization of the multiple molecular forms of staphylococcal clotting activity (coagulase)
DE3788993D1 (de) Rekombinante Ligninase.
Guerillon et al. Crossed immunoelectrophoretic characterization of Chilo iridescent virus surface antigens
Guss et al. Analysis of protein A encoded by a mutated gene of Staphylococcus aureus Cowan I
ES2059823T3 (es) Metodos y sistemas para producir antigenos de hiv.
WO1997026361A3 (en) Bacterial donor cell useful in conjugation
WO2002051992A3 (en) 21163, a novel human prolyl oligopeptidase and uses therefor
WO1998031796A8 (en) Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
RU96124779A (ru) Днк, кодирующая кератиназу bacilus licheniformis pwd-1
Vila et al. Action of thrombin of platelets. Characterization of total and membrane proteins. Platelet-fibrinogen interaction
SE9404066D0 (sv) Fusion proteins of immunopotentiating activity

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment